数据显示，鹏华基金旗下1只基金重仓阳普医疗。鹏华智投数字经济混合A（020086）二季度减持3.18万 股，持有股数2.11万股，占基金净值比例为0.62%，位居第八大重仓股。根据测算，今日浮亏损失约 8229元。连续3天下跌期间浮亏损失8651元。 鹏华智投数字经济混合A（020086）基金经理为苏俊杰。 鹏华智投数字经济混合A（020086）成立日期2024年5月17日，最新规模513.49万。今年以来收益 44.8%，同类排名1390/8172；近一年收益100.02%，同类排名638/7995；成立以来收益86.18%。 截至发稿，苏俊杰累计任职时间7年238天，现任基金资产总规模197.79亿元，任职期间最佳基金回报 84.71%， 任职期间最差基金回报-21.6%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 9月23日，阳普医疗跌5.03%，截至发稿，报7.37元/股，成交3618.07万元，换手率1.76%，总市值22.79 亿元。阳普医疗股价已经连续 ...

Group 1 - The core viewpoint of the news is that Yangpu Medical has seen a stock price increase of 5.14%, reaching 8.18 yuan per share, with a total market capitalization of 2.529 billion yuan as of the report date [1] - Yangpu Medical specializes in providing technical solutions, products, and services for clinical testing laboratories and clinical care, with its main business revenue composition being 66.48% from vacuum blood collection systems, 12.23% from reagents, and 10.03% from software products and services [1] - The company is located in Zhuhai, Guangdong Province, and was established on August 19, 1996, with its listing date on December 25, 2009 [1] Group 2 - From the perspective of fund holdings, Penghua Fund has one fund heavily invested in Yangpu Medical, specifically the Penghua Smart Investment Digital Economy Mixed A fund, which reduced its holdings by 3,180 shares in the second quarter [2] - The fund currently holds 21,100 shares of Yangpu Medical, representing 0.62% of the fund's net value, ranking as the eighth largest holding [2] - The Penghua Smart Investment Digital Economy Mixed A fund has achieved a year-to-date return of 38.26% and a one-year return of 86.81%, ranking 1303 out of 8180 and 549 out of 7978 respectively [2]

Company Overview - Yangpu Medical's stock price closed at 8.56 yuan on August 6, down 0.31 yuan, a decrease of 3.49% from the previous trading day [1] - The stock reached a high of 9.06 yuan and a low of 8.52 yuan during the day, with an overall volatility of 6.09% and a trading volume of 262 million yuan [1] Industry Position - The company operates in the medical device industry, focusing on vacuum blood collection systems and in vitro diagnostics [1] - Yangpu Medical has made investments in innovative medical technologies, including CAR-T cell therapy, positioning itself within the Guangdong region's healthcare sector [1] Market Activity - On August 6, there was a net outflow of 12.4 million yuan in principal funds, with a cumulative net outflow of 11.56 million yuan over the past five trading days [1] - The stock experienced a rapid decline after the market opened, with a drop of over 2% within the first five minutes of trading [1]

Group 1 - The stock price of Yangpu Medical closed at 8.17 yuan on July 30, with an increase of 0.10 yuan, representing a rise of 1.24% [1] - The trading volume on that day was 236,259 hands, with a transaction amount of 1.92 billion yuan [1] - Yangpu Medical operates in the medical device industry, focusing on the research, production, and sales of vacuum blood collection systems and in vitro diagnostic products, primarily used in clinical testing and disease diagnosis [1] Group 2 - On July 30, Yangpu Medical clarified on its investor interaction platform that its business does not involve products related to assisted reproduction, responding to inquiries about its offerings in obstetrics and gynecology [1] - The net inflow of main funds into Yangpu Medical was 2.0086 million yuan, accounting for 0.09% of its circulating market value [2]